Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:conditionStudied |
relapsed or refractory diffuse large B-cell lymphoma
|
| gptkbp:endPoint |
overall response rate
|
| gptkbp:enrollment |
165
|
| https://www.w3.org/2000/01/rdf-schema#label |
JULIET trial
|
| gptkbp:location |
international
|
| gptkbp:number |
NCT02445248
|
| gptkbp:period |
Phase 2
|
| gptkbp:principalInvestigator |
Stephen J. Schuster
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
demonstrated efficacy and safety of tisagenlecleucel
|
| gptkbp:resultsPublishedYear |
2019
|
| gptkbp:sponsor |
gptkb:Novartis
|
| gptkbp:startYear |
2015
|
| gptkbp:studiedDrug |
gptkb:tisagenlecleucel
|
| gptkbp:treatment |
gene therapy
|
| gptkbp:bfsParent |
gptkb:Chimeric_Antigen_Receptor_T-cell_therapy
|
| gptkbp:bfsLayer |
8
|